BIO-RAD LABORATORIES-A (BIO) Stock Fundamental Analysis
USA - NYSE:BIO - US0905722072 - Common Stock
310.02 USD
-2.37 (-0.76%)
313 USD
+2.98 (+0.96%)
Taking everything into account, BIO scores 5 out of 10 in our fundamental rating. BIO was compared to 57 industry peers in the Life Sciences Tools & Services industry. BIO has an excellent financial health rating, but there are some minor concerns on its profitability. BIO has a valuation in line with the averages, but on the other hand it scores bad on growth.
1. Profitability
1.1 Basic Checks
In the past year BIO was profitable.
BIO had a positive operating cash flow in the past year.
The reported net income has been mixed in the past 5 years: BIO reported negative net income in multiple years.
In the past 5 years BIO always reported a positive cash flow from operatings.
1.2 Ratios
BIO has a Return On Assets of 3.12%. This is in the better half of the industry: BIO outperforms 71.93% of its industry peers.
BIO's Return On Equity of 4.47% is fine compared to the rest of the industry. BIO outperforms 71.93% of its industry peers.
The Return On Invested Capital of BIO (2.36%) is better than 61.40% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for BIO is significantly below the industry average of 14.93%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 3.12% | ||
| ROE | 4.47% | ||
| ROIC | 2.36% |
ROA(3y)-17.25%
ROA(5y)0.31%
ROE(3y)-24.36%
ROE(5y)-0.68%
ROIC(3y)2.69%
ROIC(5y)2.68%
1.3 Margins
BIO has a better Profit Margin (12.49%) than 80.70% of its industry peers.
The Operating Margin of BIO (11.30%) is better than 70.18% of its industry peers.
BIO's Operating Margin has been stable in the last couple of years.
BIO has a better Gross Margin (53.00%) than 61.40% of its industry peers.
BIO's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 11.3% | ||
| PM (TTM) | 12.49% | ||
| GM | 53% |
OM growth 3Y-15.57%
OM growth 5Y1.1%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.9%
GM growth 5Y-0.31%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), BIO is destroying value.
Compared to 1 year ago, BIO has less shares outstanding
BIO has less shares outstanding than it did 5 years ago.
BIO has a worse debt/assets ratio than last year.
2.2 Solvency
BIO has an Altman-Z score of 3.31. This indicates that BIO is financially healthy and has little risk of bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 3.31, BIO is in the better half of the industry, outperforming 66.67% of the companies in the same industry.
BIO has a debt to FCF ratio of 3.46. This is a good value and a sign of high solvency as BIO would need 3.46 years to pay back of all of its debts.
The Debt to FCF ratio of BIO (3.46) is better than 75.44% of its industry peers.
BIO has a Debt/Equity ratio of 0.17. This is a healthy value indicating a solid balance between debt and equity.
BIO has a Debt to Equity ratio (0.17) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.17 | ||
| Debt/FCF | 3.46 | ||
| Altman-Z | 3.31 |
ROIC/WACC0.23
WACC10.16%
2.3 Liquidity
BIO has a Current Ratio of 5.12. This indicates that BIO is financially healthy and has no problem in meeting its short term obligations.
BIO's Current ratio of 5.12 is fine compared to the rest of the industry. BIO outperforms 70.18% of its industry peers.
A Quick Ratio of 3.67 indicates that BIO has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 3.67, BIO is in the better half of the industry, outperforming 68.42% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 5.12 | ||
| Quick Ratio | 3.67 |
3. Growth
3.1 Past
The earnings per share for BIO have decreased by -7.11% in the last year.
The Earnings Per Share has been growing slightly by 7.84% on average over the past years.
BIO shows a decrease in Revenue. In the last year, the revenue decreased by -0.33%.
Measured over the past years, BIO shows a small growth in Revenue. The Revenue has been growing by 2.11% on average per year.
EPS 1Y (TTM)-7.11%
EPS 3Y-13.02%
EPS 5Y7.84%
EPS Q2Q%-16.08%
Revenue 1Y (TTM)-0.33%
Revenue growth 3Y-4.24%
Revenue growth 5Y2.11%
Sales Q2Q%2.06%
3.2 Future
The Earnings Per Share is expected to decrease by -2.55% on average over the next years.
The Revenue is expected to grow by 1.48% on average over the next years.
EPS Next Y-5.49%
EPS Next 2Y0.38%
EPS Next 3Y3.62%
EPS Next 5Y-2.55%
Revenue Next Year0.58%
Revenue Next 2Y1.71%
Revenue Next 3Y2.22%
Revenue Next 5Y1.48%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 30.82, which means the current valuation is very expensive for BIO.
Based on the Price/Earnings ratio, BIO is valued a bit cheaper than the industry average as 70.18% of the companies are valued more expensively.
When comparing the Price/Earnings ratio of BIO to the average of the S&P500 Index (27.40), we can say BIO is valued inline with the index average.
With a Price/Forward Earnings ratio of 29.84, BIO can be considered very expensive at the moment.
BIO's Price/Forward Earnings ratio is a bit cheaper when compared to the industry. BIO is cheaper than 70.18% of the companies in the same industry.
BIO is valuated rather expensively when we compare the Price/Forward Earnings ratio to 22.94, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 30.82 | ||
| Fwd PE | 29.84 |
4.2 Price Multiples
Based on the Price/Free Cash Flow ratio, BIO is valued cheaper than 82.46% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 24.14 | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
The decent profitability rating of BIO may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)3.93
EPS Next 2Y0.38%
EPS Next 3Y3.62%
5. Dividend
5.1 Amount
BIO does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
310.02
-2.37 (-0.76%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners89.73%
Inst Owner Change-0.06%
Ins Owners3.84%
Ins Owner Change0%
Market Cap8.39B
Analysts78
Price Target317.22 (2.32%)
Short Float %6.01%
Short Ratio4.07
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)44.02%
Min EPS beat(2)38.97%
Max EPS beat(2)49.07%
EPS beat(4)4
Avg EPS beat(4)40.05%
Min EPS beat(4)0.1%
Max EPS beat(4)72.05%
EPS beat(8)7
Avg EPS beat(8)26.32%
EPS beat(12)8
Avg EPS beat(12)16.87%
EPS beat(16)12
Avg EPS beat(16)20.5%
Revenue beat(2)2
Avg Revenue beat(2)2.99%
Min Revenue beat(2)1.11%
Max Revenue beat(2)4.87%
Revenue beat(4)3
Avg Revenue beat(4)1.42%
Min Revenue beat(4)-2.71%
Max Revenue beat(4)4.87%
Revenue beat(8)3
Avg Revenue beat(8)-1.19%
Revenue beat(12)3
Avg Revenue beat(12)-1.6%
Revenue beat(16)6
Avg Revenue beat(16)-0.34%
PT rev (1m)-4.99%
PT rev (3m)-1.11%
EPS NQ rev (1m)-1.09%
EPS NQ rev (3m)17.21%
EPS NY rev (1m)0%
EPS NY rev (3m)14.35%
Revenue NQ rev (1m)-0.08%
Revenue NQ rev (3m)3.19%
Revenue NY rev (1m)-0.08%
Revenue NY rev (3m)2.95%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 30.82 | ||
| Fwd PE | 29.84 | ||
| P/S | 3.28 | ||
| P/FCF | 24.14 | ||
| P/OCF | 15.69 | ||
| P/B | 1.18 | ||
| P/tB | 1.36 | ||
| EV/EBITDA | N/A |
EPS(TTM)10.06
EY3.24%
EPS(NY)10.39
Fwd EY3.35%
FCF(TTM)12.84
FCFY4.14%
OCF(TTM)19.76
OCFY6.37%
SpS94.39
BVpS263.44
TBVpS227.28
PEG (NY)N/A
PEG (5Y)3.93
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 3.12% | ||
| ROE | 4.47% | ||
| ROCE | 2.99% | ||
| ROIC | 2.36% | ||
| ROICexc | 2.75% | ||
| ROICexgc | 3.12% | ||
| OM | 11.3% | ||
| PM (TTM) | 12.49% | ||
| GM | 53% | ||
| FCFM | 13.61% |
ROA(3y)-17.25%
ROA(5y)0.31%
ROE(3y)-24.36%
ROE(5y)-0.68%
ROIC(3y)2.69%
ROIC(5y)2.68%
ROICexc(3y)3.18%
ROICexc(5y)3.05%
ROICexgc(3y)3.46%
ROICexgc(5y)3.26%
ROCE(3y)3.41%
ROCE(5y)3.39%
ROICexcg growth 3Y8.21%
ROICexcg growth 5Y0.05%
ROICexc growth 3Y5.9%
ROICexc growth 5Y-0.58%
OM growth 3Y-15.57%
OM growth 5Y1.1%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.9%
GM growth 5Y-0.31%
F-Score6
Asset Turnover0.25
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.17 | ||
| Debt/FCF | 3.46 | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | 7.33% | ||
| Interest Coverage | -6.2 | ||
| Cash Conversion | N/A | ||
| Profit Quality | 108.94% | ||
| Current Ratio | 5.12 | ||
| Quick Ratio | 3.67 | ||
| Altman-Z | 3.31 |
F-Score6
WACC10.16%
ROIC/WACC0.23
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)5.75%
Cap/Sales(5y)5.22%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-7.11%
EPS 3Y-13.02%
EPS 5Y7.84%
EPS Q2Q%-16.08%
EPS Next Y-5.49%
EPS Next 2Y0.38%
EPS Next 3Y3.62%
EPS Next 5Y-2.55%
Revenue 1Y (TTM)-0.33%
Revenue growth 3Y-4.24%
Revenue growth 5Y2.11%
Sales Q2Q%2.06%
Revenue Next Year0.58%
Revenue Next 2Y1.71%
Revenue Next 3Y2.22%
Revenue Next 5Y1.48%
EBIT growth 1Y-15.48%
EBIT growth 3Y-19.14%
EBIT growth 5Y3.24%
EBIT Next Year33.54%
EBIT Next 3Y15.21%
EBIT Next 5Y7.17%
FCF growth 1Y125.65%
FCF growth 3Y-20.8%
FCF growth 5Y-5.83%
OCF growth 1Y86.4%
OCF growth 3Y-12.07%
OCF growth 5Y-0.12%